Open AccessThe Prevalence and Prognostic Impacts of Nucleophosmin Mutations in Adult Patients with De Novo Acute Myeloid Leukemia
Author(s) -
Noha Hassan,
Noha Ibrahim,
Khaled Aboul-Enein,
Lamyaa Nabeeh Al-Fadally,
Reem Nabil
Publication year - 2021
Publication title -
open access macedonian journal of medical sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.288
H-Index - 17
ISSN - 1857-9655
DOI - 10.3889/oamjms.2021.6172
Subject(s) - npm1 , medicine , nucleophosmin , myeloid leukemia , mutation , gene mutation , leukemia , cancer , oncology , gastroenterology , gene , karyotype , genetics , chromosome , biology
BACKGROUND: Acute myeloid leukemia (AML) is known as cancer of the blood and bone marrow (BM) and is regarded as the commonest acute leukemia in adult patients.AIM: In this study, the aim to investigate the nucleophosmin mutations and their prognostic impacts in patients that were recently diagnosed with AML.METHODS: We have included patients who were newly diagnosed with AML and presented to the medical oncology clinics, National Cancer Institute, Cairo University, during the period from August 2016 to December 2018. To assess the laboratory and hematological outcomes of our patients, total RNA was extracted from BM and converted to cDNA then the expression of nucleophosmin 1 (NPM1) type A mutation was done by real-time quantitative polymerase chain reaction (PCR). Comparative analysis was also conducted to study outcomes between the gene mutation groups.RESULTS: We have included 89 AML patients in our study with a median age of 43 years (18–77). NPM1 gene mutation was detected in 37.1% of our patients by conventional PCR technique and agarose gel electrophoresis, of which 18% were NPM1 type A mutation. No significant differences were noticed between our patients based on their NPM1 gene mutation status (wild and mutant) in terms of sex, hepatomegaly, splenomegaly, and complete remission (CR). Lymphadenopathy was the only significant factor (p = 0.023). Surprisingly we found 9/33 patients had NPM1 mutation with recurrent cytogenetic abnormality. We found no statistical significance between mutation A and mutation non-A groups in any of the studied outcomes as sex, clinical and laboratory data, and CR.CONCLUSION: NPM1 gene mutation A was relatively low among our population but did not significantly affect the outcomes.